Analyzing Ventyx Biosciences (NASDAQ:VTYX) and Lifecore Biomedical (NASDAQ:LFCR)

Ventyx Biosciences (NASDAQ:VTYXGet Free Report) and Lifecore Biomedical (NASDAQ:LFCRGet Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Risk and Volatility

Ventyx Biosciences has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.

Valuation and Earnings

This table compares Ventyx Biosciences and Lifecore Biomedical’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ventyx Biosciences N/A N/A -$192.96 million ($3.30) -1.78
Lifecore Biomedical $103.27 million 1.51 -$99.56 million ($3.35) -1.54

Lifecore Biomedical has higher revenue and earnings than Ventyx Biosciences. Ventyx Biosciences is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

97.9% of Ventyx Biosciences shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 24.4% of Ventyx Biosciences shares are owned by insiders. Comparatively, 14.6% of Lifecore Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


This table compares Ventyx Biosciences and Lifecore Biomedical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ventyx Biosciences N/A -62.58% -57.42%
Lifecore Biomedical N/A N/A N/A

Analyst Recommendations

This is a breakdown of current ratings for Ventyx Biosciences and Lifecore Biomedical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ventyx Biosciences 0 4 5 0 2.56
Lifecore Biomedical 0 1 1 0 2.50

Ventyx Biosciences currently has a consensus target price of $21.75, indicating a potential upside of 271.16%. Lifecore Biomedical has a consensus target price of $9.50, indicating a potential upside of 84.11%. Given Ventyx Biosciences’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Ventyx Biosciences is more favorable than Lifecore Biomedical.

About Ventyx Biosciences

(Get Free Report)

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

About Lifecore Biomedical

(Get Free Report)

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with's FREE daily email newsletter.